Popular Articles
Stretch Mark

Baxter Advances To Full-Scale Production Of A/H1N1 Vaccine
Baxter International Inc. (NYSE: BAX) announced that it has completed testing and evaluation of the A/H1N1 influenza virus and is now in full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology. Baxter received an A/H1N1 strain from the U.S. Centers for Disease Control and Prevention [a World Health Organization (WHO) Collaborating Center] in early May and is diligently working to deliver a pandemic vaccine for use as early as July.
generic viagra online
IMAGINEradiologyTM Attains Microsoft's Gold ISV/Software Solutions Competency
Technology Partners, Inc. (dba IMAGINE Software), a leading provider of medical billing technology, recently announced it has attained Gold Certified Partner status in the Microsoft Partner Program with its flagship product IMAGINEradiologyTM, which achieved an ISV/Software Solutions Competency. The company also received a Networking Infrastructure Solutions Competency, recognizing Technology Partners" expertise and impact in the technology marketplace.
News of the day
BioCryst Pharmaceuticals Announces Presentation Of Forodesine Data At The 45th Annual Meeting Of The American Society Of Clinical Oncology
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced long-term data from a Phase 2 study of forodesine, the Company"s lead oncology compound, in patients with cutaneous T-cell lymphoma (CTCL). The data will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Orlando, Florida from May 29-June 2. Forodesine is a transition-state analog inhibitor of purine nucleoside phosphorylase (PNP), a purine salvage pathway enzyme that is essential for the proliferation of T-cells and B-cells.
Mental Health

Minister Aglukkaq Announces Re-Appointments To The Canadian Institutes Of Health Research Governing Council

The Honourable Leona Aglukkaq, Minister of Health, today announced the re-appointments of Dr. Jean Rouleau and Dr. Brett Finlay to the Canadian Institutes of Health Research (CIHR) Governing Council for their second three-year terms. "Drs. Rouleau and Finlay are among the best and brightest minds in their respective fields and both men bring invaluable expertise to CIHR"s Governing Council," said Minister Aglukkaq. "Thanks to these re-appointments, both members will be able to continue the work that they have already started in helping CIHR meet its mandate of improving the health of all Canadians." Dr. Jean Rouleau is the Dean of the Faculty of Medicine at the University of Montreal and practises cardiology at the Montreal Heart Institute. Dr. Rouleau is a respected and world-famous cardiac researcher, with over 300 published articles. He has a deep understanding of teaching, research and care settings and will continue to make key contributions to Governing Council based on his experience. He has been the recipient of numerous awards, including the Quebec Medical Association"s Prix Prestige, the Canadian Centennial Medal, the Canadian Cardiovascular Society"s Career Research Achievement Award, and the 2009 Henry Friesen Award from the Canadian Society for Clinical Investigation and the Royal College of Physicians and Surgeons of Canada. Dr. B. Brett Finlay is a Professor in the Michael Smith Laboratories, and the Departments of Biochemistry and Molecular Biology, and Microbiology and Immunology at the University of British Columbia. He has made several fundamental discoveries in the emerging field of cellular microbiology and has published over 300 papers. Dr. Finlay is recognized internationally for his work and is an Officer of the Order of Canada and the Order of British Columbia. He is a cofounder of Inimex Pharmaceuticals Inc., and Director of the SARS Accelerated Vaccine Initiative. He is a strong supporter of communicating science to the public. Dr. Finlay will continue to play a leadership role on Governing Council and its committees. The biographies for the members of the CIHR Governing Council can be found at The Canadian Institutes of Health Research website. CIHR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):